David Miklos, MD, PhD: Ibrutinib in Chronic Graft-Versus-Host Disease

For patients who experience graft-versus-host disease after transplant and do not respond to corticosteroids, ibrutunib leads to a high, durable response rate, according to results from a phase II trial. Dr. Miklos discusses these results.

SHARE